AstraZeneca Vaccine is 100 percent effective against severe COVID-19 disease

COVID-19 Vaccine by AstraZeneca provides 100 percent protection against severe disease and hospitalization.

COVID-19 Vaccine by AstraZeneca provides 100 percent protection against severe disease and hospitalization. According to the phase III clinical trials in the U.S., the Oxford-AstraZeneca vaccine is 79 percent effective against symptomatic disease and offers 100 percent protection against severe illness and hospitalizations. In a press release, the British-Swedish pharmaceutical company highlighted the degree of vaccine effectiveness, with 80 percent efficacy in participants aged 65 years and over. The clinical trials consisted of 32,449 participants, of which the majority were white/Caucasian.

Despite showing high efficacy results, the safety of the Oxford-AstraZeneca vaccine has repeatedly been in question. Several European countries, including Norway and Germany, halted the AstraZeneca vaccine drive after some people reported getting blood clots, particularly Cerebral Venous Sinus Thrombosis (CVST), upon receiving the jab. In the phase III trials, an independent data safety monitoring board (DSMB) conducted a review of thrombotic events and CVST. The study found no increased risk of thrombosis among the 21,583 participants who received at least one dose of the vaccine. Health regulatory boards such as the World Health Organisation, Europe's European Medicines Agency, and U.K.'s Medicines and Healthcare products Regulatory Agency have deemed the vaccine safe and effective.

AstraZeneca will submit the results from the trials to the U.S. Food and Drug Administration for Emergency Use Authorisation in the coming weeks.

The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.